Pharmacological management of osteoporosis – when to treat and when to stop

References

• Cosman F, de Beur SJ, LeBoff MS, et al. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. [PubMed: 25182228].
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Bisphosphonates for the treatment of osteoporosis: insights for clinicians. Ther Adv Chronic Dis. 2010;1(3):115–128. [PubMed: 23251734].
   PubMedGoogle Scholar
• Black DM, Rosen CJ. Clinical Practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–262. Review. [PubMed: 26789873].
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243–254. [PubMed: 22161728].
   PubMed Web of Science ®Google Scholar
• Mellström DD, Sörensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75(6):462–468. [PubMed: 15455188].
   PubMed Web of Science ®Google Scholar
• Watts NB, Geusens P, Barton IP, et al. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005;20(12):2097–2104. [PubMed: 16294263].
   PubMed Web of Science ®Google Scholar
• Watts NB. Long-term risks of bisphosphonate therapy. Arq Bras Endocrinol Metab. 2014;58(5):523–529. Review. [PubMed: 25166043].
   PubMed Web of Science ®Google Scholar
• McClung M, Harris ST, Miller PD, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med. 2013;126(1):13–20. Review. [PubMed: 23177553].
   PubMed Web of Science ®Google Scholar
• Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a Task Force of the American Society for bone and mineral research. J Bone Miner Res. 2016;31(1):16–35. Review. [PubMed: 26350171].
   PubMed Web of Science ®Google Scholar
• Recker RR, Ste-Marie LG, Chavassieux P, et al. Bone safety with risedronate: histomorphometric studies at different dose levels and exposure. Osteoporos Int. 2015;26(1):327–337. [PubMed: 25304456].
   PubMed Web of Science ®Google Scholar
• Black DM, Bauer DC, Schwartz AV, et al. Continuing bisphosphonate treatment for osteoporosis—for whom and for how long? N Engl J Med. 2012;366(22):2051–2053. [PubMed: 22571169].
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Bauer DC, Cummings SR, et al. FLEX Research Group. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial. J Bone Miner Res. 2010;25(5):976–982. [PubMed: 20200926].
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-Term Extension (FLEX): a randomized trial. Jama. 2006;296(24):2927–2938. [PubMed: 17190893].
   PubMed Web of Science ®Google Scholar
• Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Fracture Intervention Trial Long-Term Extension Research Group. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension. J Bone Miner Res. 2004;19(8):1259–1269. [PubMed: 15231012].
   PubMed Web of Science ®Google Scholar
• Diab DL, Watts NB. Bisphosphonate drug holiday: who, when and how long. Ther Adv Musculoskelet Dis. 2013;5(3):107–111. [PubMed: 23858334].
   PubMedGoogle Scholar
• Jacques RM, Boonen S, Cosman F, et al. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(8):1627–1634. [PubMed: 22532515].
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2015;30(5):934–944. [Pubmed: 25545380].
   PubMed Web of Science ®Google Scholar
• Reginster J, Minne HW, Sorensen OH, et al. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11(1):83–91. [PubMed: 10663363].
   PubMed Web of Science ®Google Scholar
• Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003;32(2):120–126. [PubMed: 12633783].
   PubMed Web of Science ®Google Scholar
• Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk—a perspective. J Bone Miner Res. 2012;27(5):963–974. Review. [PubMed: 22467094].
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al. FREEDOM trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765. [PubMed: 19671655].
   PubMed Web of Science ®Google Scholar
• Austin M, Yang YC, Vittinghoff E, et al. FREEDOM Trial. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012;27(3):687–693. [PubMed: 22095631].
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694–701. [PubMed: 22113951].
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483–4492. [PubMed: 23979955].
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26(12):2773–2783. [PubMed: 26202488].
   PubMed Web of Science ®Google Scholar
• Watts NB, Chines A, Olszynski WP, et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int. 2008;19(3):365–372. [PubMed: 17938986].
   PubMed Web of Science ®Google Scholar
• Bone HG, Hosking D, Devogelaer JP, et al. Alendronate Phase III Osteoporosis Treatment Study Group. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350(12):1189–1199. [PubMed: 15028823].
   PubMed Web of Science ®Google Scholar
• Delmas PD. Use of alendronate after 5 years of treatment. Jama. 2007;297(18):1979–1981. [PubMed: 17488957].
   PubMed Web of Science ®Google Scholar
• Cosman F, Cauley JA, Eastell R, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014;99(12):4546–4554. [PubMed: 25215556].
   PubMed Web of Science ®Google Scholar
• Adami S, Idolazzi L, Fracassi E, et al. Osteoporosis treatment: when to discontinue and when to re-start. Bone Res. 2013;1(4):323–335. Review. [PubMed: 26273510].
   PubMed Web of Science ®Google Scholar
• Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164(18):2024–2030. [PubMed: 15477438].
   PubMedGoogle Scholar
• Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res. 2005;20(9):1507–1513. [PubMed: 16059622].
   PubMed Web of Science ®Google Scholar
• Miller PD, Wagman RB, Peacock M, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab. 2011;96(2):394–402. [PubMed: 21159841].
   PubMed Web of Science ®Google Scholar
• Miller PD, Bolognese MA, Lewiecki EM, et al. Amg Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–229. [PubMed: 18539106].
   PubMed Web of Science ®Google Scholar
• Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972–980. [PubMed: 21289258].
   PubMed Web of Science ®Google Scholar
• Bauer DC, Schwartz A, Palermo L, et al. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014;174(7):1126–1134. [PubMed: 24798675].
   PubMed Web of Science ®Google Scholar